Can Austedo (deutetrabenazine) be used to treat medication‑induced extrapyramidal symptoms (EPS)?

No, Austedo (deutetrabenazine) does not treat medication-induced extrapyramidal symptoms (EPS)—it treats tardive dyskinesia, which is a specific type of late-onset movement disorder, not acute EPS.

Austedo is FDA-approved specifically for tardive dyskinesia (TD), not for acute extrapyramidal symptoms like dystonia, parkinsonism, or akathisia 1. This is a critical distinction that directly impacts patient safety and treatment outcomes.

Understanding the Distinction

What Austedo Actually Treats

Austedo (deutetrabenazine) is a VMAT2 inhibitor approved for:

• Tardive dyskinesia: A late-onset, potentially irreversible movement disorder characterized by involuntary choreic or athetoid movements, typically in the orofacial region 1, 2, 3
• Huntington's disease chorea: Not relevant to medication-induced EPS 1

The drug demonstrated efficacy in TD with a Number Needed to Treat (NNT) of 5-7 for achieving AIMS response 3.

What Constitutes Acute EPS (Which Austedo Does NOT Treat)

Acute extrapyramidal symptoms include 4, 5:

1. Acute dystonia: Sudden spastic muscle contractions (neck, eyes, torso)

   • Treatment: Anticholinergics (e.g., benztropine) or antihistamines
   • Responds well to these agents, often within minutes

2. Drug-induced parkinsonism: Bradykinesia, tremors, rigidity

   • Treatment: Anticholinergics or dopaminergic agents like amantadine 4

3. Akathisia: Severe restlessness and motor agitation

   • Treatment: Dose reduction of offending agent, β-blockers, or benzodiazepines 4
   • Notably difficult to treat

Critical Safety Concern: Austedo Can WORSEN Acute EPS

Austedo carries significant warnings about causing or exacerbating parkinsonism and akathisia 1:

• The FDA label explicitly warns that deutetrabenazine "may cause parkinsonism" and "may increase the risk of akathisia, agitation, and restlessness" 1
• Postmarketing cases document parkinsonism development in patients treated with Austedo, including bradykinesia, gait disturbances leading to falls, and emergence or worsening of tremor 1
• Most cases occurred within the first two weeks of starting or increasing the dose 1
• Management requires dose reduction or discontinuation—the opposite of what you'd want if trying to treat EPS 1

The Correct Treatment Algorithm for Medication-Induced EPS

For Acute Dystonia 4, 5:

• Immediate treatment: Anticholinergics (benztropine, diphenhydramine) or antihistamines
• Life-threatening laryngeal dystonia requires emergency intervention
• Response is typically rapid and complete

For Drug-Induced Parkinsonism 4:

• First-line: Anticholinergic agents or amantadine
• Consider dose reduction of offending antipsychotic
• Switch to atypical antipsychotic if feasible

For Akathisia 4:

• First approach: Lower the antipsychotic dose if clinically feasible
• Pharmacologic options: β-blockers or benzodiazepines (antiparkinsonian agents are inconsistently helpful)
• This is often the most challenging acute EPS to manage

Prophylaxis Considerations 4:

• Prophylactic antiparkinsonian agents may be considered for patients at high risk for acute dystonias (young age, male gender, high-potency agents)
• Particularly important for patients with compliance concerns
• Re-evaluate need after acute phase or with dose reductions

When Austedo IS Appropriate: Tardive Dyskinesia

If a patient develops tardive dyskinesia (not acute EPS), then Austedo becomes a treatment option 1, 2, 3:

• Start at 6 mg twice daily with food
• Titrate weekly in 6 mg/day increments based on TD reduction and tolerability
• Maximum dose: 48 mg/day (24 mg twice daily)
• Monitor for development of parkinsonism or akathisia as potential adverse effects 1

TD vs. Acute EPS Differentiation:

• TD: Late-onset (typically after months-years of antipsychotic exposure), involuntary choreic movements, may persist after drug discontinuation 4
• Acute EPS: Early-onset (days to weeks), includes dystonia/parkinsonism/akathisia, typically resolves with appropriate treatment or drug discontinuation

Real-World Evidence

Recent Medicaid claims data showed that among patients with schizophrenia who developed EPS after SGA initiation, 92.6% were treated with benztropine, while less than 2% received deutetrabenazine or valbenazine—and those receiving VMAT2 inhibitors were specifically being treated for TD, not acute EPS 6.

Bottom Line

Using Austedo to treat acute medication-induced EPS would be both ineffective and potentially harmful, as it can worsen parkinsonism and akathisia. Acute EPS requires anticholinergics, antihistamines, β-blockers, or benzodiazepines depending on the specific syndrome. Reserve Austedo exclusively for tardive dyskinesia, which is a distinct, late-onset movement disorder requiring a fundamentally different therapeutic approach.